Today’s Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics

NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Enanta Pharmaceuticals as well as Vascular Biogenics were two stocks in the biotech arena making big moves in Wednesday’s trading session. Enanta climbed higher despite any remarkable news from the company while Vascular Biogenics soared on impressive data released at the 2018 BIO International Convention.

RDI Initiates Coverage on:

Enanta Pharmaceuticals, Inc.
https://www.rdinvesting.com/report/?ticker=ENTA

Vascular Biogenics Ltd.
https://www.rdinvesting.com/report/?ticker=VBLT

Enanta Pharmaceuticals, Inc. shares closed up 9.62% on about 353,000 shares traded yesterday. The stock hit a brand new high of $109.93 despite any catalyst or news. The research and development-focused biotechnology company’s CEO Jay R. Luly, will make a presentation followed by a question and answer session at the NASDAQ 38th Investor Conference on June 12 at 9:30 a.m. GMT in London. The company has used its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery of small molecule drugs for the treatment of viral infections and liver diseases. It was about a month ago that the company posted its second quarter financial results, revealing net income of $12.6 million. In the year ago period the company had posted a loss. Profit was 61 cents a share and revenue was $44 million.

Access RDI’s Enanta Pharmaceuticals, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=ENTA

Vascular Biogenics Ltd. shares closed up almost 40% on Wednesday with about 5.8 million shares traded. The biotech company saw its shares explode in after hours trading on Tuesday after presenting data on its novel MOSPD2 program in oncology and inflammation at the 2018 BIO International Convention. The data found that MOSPD2 plays a key role in the regulation of cell motility. CEO Dror Harats, M.D., stated, “We have generated data indicating that MOSPD2 is required for directional movement, or chemotaxis, of tumor cells and certain immune cells, and therefore appears to play a central role in both oncology and inflammation. We continue to advance our exciting VB-600 series of antibodies as drug candidates for oncology and inflammatory indications.” MOSPD2 can be found in many types of solid tumors.

Access RDI’s Vascular Biogenics Ltd. Research Report at:
https://www.rdinvesting.com/report/?ticker=VBLT

Our Actionable Research on Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) and Vascular Biogenics Ltd. (NASDAQ: VBLT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 502003